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ABSTRACT
Background Increased levels of vascular endothelial growth factor (VEGF) have been observed in patients with
metabolic syndrome (MetS). Nitric oxide (NO) formation is reduced in MetS, but its relationship to VEGF produc-
tion remains poorly defined. We evaluated the association between VEGF ⁄NO synthesis and insulin sensitivity
in obese subjects and investigated the secretory response of VEGF to an acute elevation of glucose.
Materials and methods Seven healthy normal-weight subjects, seven obese subjects without MetS and seven
obese subjects with MetS were recruited. Anthropometry, body composition and cardiometabolic functions
(blood pressure, glucose, insulin, triglycerides, total cholesterol, HDL-C and VEGF) were measured, and a novel
stable isotope method was used to assess in vivo rates of NO production. A frequent sampling intravenous glu-
cose tolerance test was performed to study the dynamics of VEGF release.
Results Fasting VEGF levels were significantly higher in the two obese groups compared to the control group (P
for trend = 0Æ02), but the difference was not significant after adjustment for age. Vascular endothelial growth
factor levels were associated with systolic blood pressure (q = 0Æ54; P = 0Æ01) and NO production (q = )0Æ44;
P = 0Æ04). Vascular endothelial growth factor levels increased in response to acute hyperglycaemia in normal-
weight and obese subjects (P < 0Æ001).
Conclusions Vascular endothelial growth factor levels rapidly increase during hyperglycaemia and are inversely
related to NO production at steady state. The potential link between the acute secretion of VEGF and atheroscle-
rotic risk in subjects with poorly controlled glycaemia as well as the potential of lowering elevated VEGF levels
by increasing NO production and ⁄or availability warrants further investigation.
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Introduction
Angiogenesis is involved in the formation of new vascular net-
works in physiology (embryo ⁄ organogenesis, pregnancy,
wound healing) and pathology (cancer, psoriasis) [1], and
de-novo formation and remodelling of blood vessels are
important events in the atherosclerotic process. Current
research is investigating the role of angiogenesis as a risk factor
for atherosclerosis and excess adiposity [2,3].
Vascular endothelial growth factor levels were directly
associated with body mass index (BMI) but not with insulin
sensitivity in obese and normal-weight subjects [4]. Plasma
VEGF levels were significantly associated with features of the
metabolic syndrome (MetS) such as BMI, waist circumference,
blood pressure and inflammation [5,6].
In vivo rates of nitric oxide (NO) synthesis are lower in
metabolic disorders associated with insulin resistance [7]. In
addition, we have recently demonstrated a reduction in NO
production in obese subjects with MetS [8] and a direct associa-
tion with insulin sensitivity [9], suggesting that VEGF may be
inversely associated with NO production and insulin sensitiv-
ity. Here, we investigated this hypothetical association by com-
paring levels of VEGF in obese subjects with and without MetS
to normal-weight controls. In addition, the acute secretory
1The material presented in this manuscript is original and has not been
submitted for publication elsewhere while under consideration for
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response of VEGF to an intravenous glucose bolus was investi-
gated in controls and obese subjects.
Methods
Subjects
Fourteen obese subjects (BMI: 30–40 kg ⁄m2) and seven normal-
weight subjects (BMI: 18Æ5–25Æ0 kg ⁄m2) were recruited. Seven
obese subjects had three or more criteria for the metabolic
syndrome. All subjects gave written informed consent before
participating in the study. The study was approved by the
Cambridgeshire four Research Ethics Committee. Participants
were excluded if they had any condition or were taking any
medication that may have interfered with the analyses. A full
description of the exclusion criteria is reported in the Online
Supporting Information. Reporting of the study conforms to
STROBE statement along with references to STROBE and the
broader EQUATOR guidelines [10].
Screening visit
Body mass index was calculated, with weight and height mea-
sured to the nearest 0Æ1 kg ⁄ cm. Waist circumference was mea-
sured in triplicate. Body fat was measured using a leg-to-leg
bio-impedance analyser (Tanita Corporation, Japan). Resting
blood pressure was measured in triplicate using an automated
sphygmomanometer (Dynamap, Critikon, UK), with a larger
cuff for obese subjects. Blood and kidney function tests were
performed after an overnight fast to ensure that participants
met the inclusion criteria. The diagnosis of MetS was made
according to the recent criteria proposed in a joint statement by
the major diabetes, obesity and heart organisations [11], which
requires at least three of the following criteria be fulfilled: waist
circumference (WC) ‡ 102 cm (man), ‡ 88 cm (woman); trigly-
cerides (TG) ‡ 1Æ7 mM; high-density lipoproteins (HDL-C)
< 1Æ3 mM (man), < 1Æ1 mM (woman); high blood pressure
‡ 130 ⁄ 85 mmHg; fasting plasma glucose ‡ 5Æ6 mM.
Frequent sampling intravenous glucose tolerance
test (FSIVGTT)
Subjects arrived in the morning to the research unit after they
had fasted for at least 12 h and followed the low NO3 diet for
24 h as part of the Salivary Oral Nitrate Test (S-ONT) used for
the measurement of NO production [8]. Two cannulae were
inserted in the antecubital vein, one in each arm. Three blood
samples were taken before the administration of glucose to
measure baseline insulin and glucose levels. An intravenous
glucose dose (1Æ75 g of [6,6]-2H2-glucose to 19 g unlabelled glu-
cose in the form of a 50% aqueous solution) was then given over
1 min. Twenty minutes after glucose administration, 201 mU of
Human Actrapid insulin was given. A total of 30 blood samples
were taken at )10, )5, )1, 1, 2, 3, 4, 5, 6, 8, 10, 13, 15, 20, 25, 30,
35, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 210 and 240 min
relative to the administration of glucose. Insulin sensitivity (Si)
was characterised by the minimal model as defined by Berg-
man et al. [12]. The plasma glucose and insulin concentrations
during the FSIVGTT are showed in Figure S1 of the online
Data S1. After the FSIVGTT, subjects were served a very low
NO3 meal as part of the oral nitrate test protocol (ONT).
A description of the meals and the low NO3 diet provided have
been previously described [8] and it is reported in the Online
Supporting Information.
Salivary oral nitrate test (S-ONT)
After the low NO3 meal, each participant was instructed not
to eat and to drink only low NO3 bottled water (Buxton) until
the following morning (18-h fasting period). Four hours after
the meal, a pre-dose saliva sample was collected and a dose
of 4 mg of Na15NO3 was given as a drink in 100 mL of
distilled water. Each subject was asked to provide another
saliva sample 2 h later. All subsequent saliva samples were
collected by the volunteer at home using pre-labelled contain-
ers. The protocol for the collection of saliva samples has been
previously described [8]. The final saliva sample was collected
18 h after the meal on the following morning. NO production
was estimated by analysing the isotopic decay in saliva of an
oral dose of labelled NO3 using an exponential function for a
single compartment. Data were described using a semi-
logarithmic plot, and the slope and intercept of the regression
line were used to derive NO synthesis, as previously
described [8].
Materials
Trifluoroacetic anhydride (TFAA), sodium hydroxide and
mesityline were obtained from Sigma-Aldrich Company Ltd,
Poole, Dorset, UK. All the stable isotopically labelled
compounds, 15N-sodium nitrate (98%+), [6,6]-2H2-glucose
(98%+) were obtained from Cambridge Isotope Laboratories
Inc, Andover, MA, USA.
Nitrate measurements
Salivary nitrate concentrations were measured using a commer-
cial 96-well kit (Cayman Chemical Co, Ann Arbor, MI, USA).
15N enrichment of nitrate was measured by gas chromatogra-
phy mass spectrometry (GC ⁄MS) following derivatisation of
saliva samples with mesitylene and TFAA as catalyst to give a
single product, nitromesitylene (1,3,5-trimethyl nitrobenzene),
as previously described [13].
Glucose enrichment measurement
Plasma glucose enrichments were analysed by GC ⁄MS after
derivatisation with fluorinated methyl boronic acid, as
previously described [14].
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Clinical biochemistry
Blood (full blood count, glucose, insulin, Hb1Ac), lipid profile
(HDL-C, LDL-C, triglycerides and total cholesterol), C reactive
protein (CRP) and kidney function tests (urea, creatinine) were
measured using validated methods. Plasma asymmetric dime-
thylarginine (ADMA) levels were measured by competitive
ELISA (Immunodiagnostik, Belsham, Germany). Plasma VEGF
concentrations were measured using an enzyme-linked immu-
nosorbent assay (Quantikine; R&D Systems, Minneapolis,
MN, USA).
Statistical analysis
Some of the results presented in this manuscript have been
reported elsewhere [8]. Data are shown as mean and standard
deviation (SD). The Kruskal–Wallis and the Mann–Whitney test
were used to test for differences between groups. The Friedman
test was used to test within-group differences in VEGF levels
during acute hyperglycaemia. Analysis of covariance for
repeated measures was used to assess VEGF changes during
acute hyperglycaemia after including age in the model as
covariate. Time (T) was the repeated measure factor, and group
(G) was entered as the between-subject factor. The interaction
term (T · G) was built to assess between-group differences in
VEGF responses during hyperglycaemia. Variables entered into
the model were transformed using the rank transformation
method to account for the small sample size and deviation from
normality distribution [15]. The Spearman rank correlation
(unadjusted and age-adjusted) was used to assess the associa-
tion between VEGF and cardiovascular and metabolic parame-
ters. All statistical analyses were carried out using SPSS 16 for
Windows (SPSS Inc., Chicago, IL, USA). The significance level
was set at 0Æ05.
Results
The baseline characteristics of the study participants are
shown in Table 1. Subjects in the control group were signif-
icantly younger and had a better overall metabolic profile
than those in either obese group. There were no differences
between groups for kidney function, glucose, diastolic blood
pressure and HDL-C. Plasma levels of insulin, triglycerides
and total cholesterol were significantly higher in the obese
group with MetS. The control group had higher values of
Si compared to the two obese groups. In contrast, rates of
NO synthesis were significantly lower in the obese group
with MetS compared to the control and obese without MetS
groups. Differences in NO production remained significant
after age adjustment (P = 0Æ006). Fasting VEGF levels
were significantly higher in the two obese groups compared
to the control group (P for trend = 0Æ02), but the differ-
ence was no longer significant after adjustment for age
(Table 1).
Vascular endothelial growth factor concentrations were
directly correlated with age, BMI, WC, fat mass (FM), SBP and
fasting insulin and inversely related to insulin sensitivity and
NO production. After age adjustment, only SBP and NO syn-
thesis remained significantly associated with VEGF levels.
Vascular endothelial growth factor levels were not significantly
associated with biomarkers of endothelial dysfunction (ADMA)
and inflammation (CRP) (Table 2).
Plasma VEGF levels rapidly increased in response to rising
plasma glucose levels during the initial phase of the FSIVGTT.
The increase in VEGF levels remained significant after age
adjustment (P < 0Æ001), and the proportional changes relative to
baseline after 19 min were 67% for the control group
(P = 0Æ003), 70% for the obese without MetS (P = 0Æ003) and
39% for the obese group with MetS (P = 0Æ54). The interaction
term (T · G) in the adjusted model was not significant
(P = 0Æ09), which indicates a similarity in VEGF responses to
hyperglycaemia between the three groups (Fig. 1).
Discussion
Obese subjects with MetS had significantly lower levels of NO
production and insulin sensitivity compared to obese subjects
without MetS and normal-weight subjects. Fasting NO and SBP
were significantly correlated with VEGF levels, which may sug-
gest interplay of these factors in the development of endothelial
dysfunction in obesity. Hyperglycaemia induced a rapid
increase in VEGF levels, and the responses were greater in nor-
mal-weight and obese subjects without MetS. The difference
between the two obese groups may be related to the higher
degree of endothelial dysfunction associated with MetS, poten-
tially translating into slower signal transduction and a delayed
VEGF secretory response. This assumption could not be experi-
mentally tested in our protocol as an insulin bolus was admin-
istered at 20 min, confounding the effects of hyperglycaemia on
VEGF secretion (no VEGF levels were measured past 20 min).
This study revealed a reciprocal association between NO
production and VEGF levels using for the first time a validated
stable isotope method for the measurement of in vivo rates of
whole-body NO production [8]. A reciprocal relationship
between NO and VEGF production has been observed in cellu-
lar models [16] but these results are not consistent with human
studies [17,18]. Specifically, two studies have reported lower
plasma nitrate levels, used as an index of NO production and
decreased VEGF levels in obese subjects with MetS [17] and
hypertension [18]. The decrease in VEGF levels observed in
these two studies contrasts with the increase in VEGF levels
observed in subjects with obesity [19], MetS [5], hypertension
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[20], type 2 diabetes with and without microvascular complica-
tions (nephropathy, retinopathy)[21], coronary heart disease
[22] and peripheral artery disease [22]. In diabetic and nondia-
betic obese subjects [23] and in hypertensive patient with and
without retinopathy [20], flow-mediated dilation of the brachial
artery in response to reactive hyperaemia was inversely associ-
ated with the levels of VEGF. Valabhji et al. [24] showed that
elevated VEGF levels in patients with type 1 diabetes correlated
with decreased carotid artery distensibility. Moreover, VEGF
directly correlated with carotid-to-intima media thickness in
909 healthy subjects (BMI = 26Æ5 ± 4Æ2 kg ⁄m2) from the Salz-
burg Atherosclerosis Prevention Program in Subjects at High
Individual Risk (SAPHIR)[25]. Thus, our results are in agree-
ment with a robust direct association between VEGF and endo-
thelial dysfunction, suggesting potential new therapeutic
avenues targeting elevated VEGF levels by enhancing NO pro-
duction and ⁄or availability.
The VEGF response to controlled hyperglycaemia in the
obese without MetS and normal-weight controls suggests that
endothelial cells are sensitive to acute changes in metabolic
fluxes, which may be a physiological response to cellular
changes in redox status and related to increased nutrient
uptake. Insulin stimulates VEGF expression [26], and a recent
study has demonstrated a role of VEGF-B in endothelial fatty
acids uptake [27]. A significant direct correlation between
plasma VEGF concentration and HbA1c has been observed in
Table 1 Baseline characteristics of the control group and of the two obese groups divided according to the diagnosis of metabolic
syndrome (MetS)
Controls Obese without MetS Obese with MetS P value
N 7 7 7
M ⁄ F 3 ⁄ 4 1 ⁄ 6 3 ⁄ 4
Age (years) 27Æ4 (10Æ9) 48Æ0 (8Æ0) 48Æ0 (10Æ7) 0Æ01a,b
Weight (kg) 65Æ2 (16Æ2) 95Æ7 (11Æ8) 103Æ9 (10Æ7) 0Æ001a,b
Height (cm) 171Æ0 (14Æ0) 166Æ4 (9Æ8) 176Æ1 (5Æ4) 0Æ24
Body mass index (kg ⁄m2) 21Æ9 (2Æ2) 34Æ5 (2Æ3) 33Æ4 (2Æ9) 0Æ001a,b
Waist circumference (cm) 78Æ0 (10Æ7) 109Æ9 (8Æ5) 111Æ3 (5Æ1) 0Æ001a,b
Systolic blood pressure (mmHg) 106Æ7 (8Æ3) 120Æ3 (13Æ1) 130Æ1 (11Æ6) 0Æ01b
Diastolic blood pressure (mmHg) 64Æ4 (10Æ2) 74Æ2 (10Æ2) 76Æ0 (7Æ7) 0Æ16
Glucose (mmol ⁄ L) 4Æ3 (0Æ4) 4Æ7 (0Æ4) 4Æ9 (0Æ5) 0Æ20
Insulin (pmol ⁄ L) 28Æ8 (6Æ8) 48Æ8 (18Æ1) 56Æ5 (12Æ5) 0Æ004a,b
Triglycerides (mmol ⁄ L) 0Æ8 (0Æ3) 1Æ1 (0Æ3) 1Æ8 (0Æ4) 0Æ006b
HDL-C (mmol ⁄ L) 1Æ5 (0Æ3) 1Æ5 (0Æ1) 1Æ2 (0Æ1) 0Æ07
Total cholesterol (mmol ⁄ L) 4Æ4 (0Æ7) 5Æ9 (1Æ2) 6Æ1 (1Æ4) 0Æ05b
Creatinine (mmol ⁄ L) 74Æ7 (11Æ9) 63Æ0 (6Æ8) 78Æ7 (17Æ4) 0Æ09
Urea (mmol ⁄ L) 4Æ0 (1Æ3) 4Æ5 (0Æ6) 5Æ2 (0Æ1) 0Æ16
CRP (mg ⁄ L) 0Æ98 (0Æ63) 3Æ37 (1Æ66) 2Æ97 (1Æ90) 0Æ01a,b
ADMA (lmol ⁄ L) 0Æ44 (0Æ07) 0Æ48 (0Æ06) 0Æ59 (0Æ08) 0Æ02b,c
Insulin sensitivity (pmol ⁄h ⁄ L) 0Æ012 (0Æ008) 0Æ0057 (0Æ0026) 0Æ0052 (0Æ0031) 0Æ05a,b
Nitric oxide synthesis (lmol ⁄ kg ⁄h) 0Æ63 (0Æ29) 0Æ49 (0Æ22) 0Æ21 (0Æ13) 0Æ009b,c
VEGF (pg ⁄mL) 11Æ01 (4Æ09) 20Æ70 (9Æ35) 18Æ86 (4Æ70) 0Æ02a,b
Mean (SD) is shown. Significant results are shown in bold. Kruskal–Wallis test was used to test for differences across the three groups (trends). The
Mann–Whitney test was utilised in a post hoc analysis to compare the individual groups. Letters indicate statistical significance between groups (P < 0Æ05).
VEGF, vascular endothelial growth factor; CRP, C reactive protein; ADMA, asymmetric dimethylarginine.
aControl vs. Obese without MetS.
bControl vs. Obese with MetS.
cObese with MetS vs. Obese without MetS.
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patients with diabetes [21], suggesting that chronic hyperglyca-
emia may increase VEGF secretion and that reduction in
elevated levels of VEGF may be possible with improved gly-
caemic control [28]. However, Loebig et al. [4] showed a lack of
association of VEGF with insulin sensitivity in normal-weight
and obese subjects, and VEGF levels remained unchanged in
patients with type 1 diabetes after 210 min of hyperglycaemia
(12Æ0 mM) and normoglycaemic (5Æ0 mM) clamps with high
(120 mU ⁄kg ⁄h) and standard insulin infusions (30 mU ⁄kg ⁄h),
respectively [29].
The cross-sectional design and the small sample size were
important limitations of this study, and the results should
therefore be interpreted with caution. In addition, a signifi-
cantly younger control group may have confounded the associ-
ation. We purposely chose this group as the reference
population to remove potential age-related changes in hor-
monal and cardiometabolic functions to evaluate the deviation
of NO production measured in obese, insulin-resistant individ-
uals from optimal, physiological rates. The analyses were
adjusted for age to account for the potential confounding effect.
Nevertheless, ours is the first report of a reciprocal relationship
between NO production, as measured using stable isotope
tracers, and plasma VEGF levels and the magnitude of acute
increases in VEGF secretion during hyperglycaemia. These
Table 2 Unadjusted and age-adjusted correlation between vascular endothelial growth factor (VEGF, pg ⁄mL) and the main
measures of metabolic and cardiovascular function
Unadjusted Adjusted for age
Rho coefficient P value Rho coefficient P value
Age (years) 0Æ56 0Æ008 – –
Body mass index (kg ⁄m2) 0Æ56 0Æ008 0Æ40 0Æ07
Waste circumference (cm) 0Æ63 0Æ002 0Æ42 0Æ06
Systolic blood pressure (mmHg) 0Æ72 < 0Æ001 0Æ54 0Æ01
Diastolic blood pressure (mmHg) 0Æ24 0Æ28 )0Æ15 0Æ54
Glucose (mmol ⁄ L) 0Æ32 0Æ14 0Æ02 0Æ93
Insulin (pmol ⁄ L) 0Æ54 0Æ01 0Æ36 0Æ11
Cholesterol (mmol ⁄ L) 0Æ04 0Æ83 )0Æ30 0Æ18
Triglycerides (mmol ⁄ L) 0Æ22 0Æ31 )0Æ05 0Æ83
HDL-C (mmol ⁄ L) )0Æ22 0Æ31 )0Æ14 0Æ55
CRP (mg ⁄ L) 0Æ32 0Æ15 0Æ12 0Æ62
ADMA (lmol ⁄ L) 0Æ17 0Æ46 )0Æ14 0Æ55
NO synthesis (lmol ⁄h ⁄ kg) )0Æ50 0Æ02 )0Æ44 0Æ04
Insulin sensitivity (pmol ⁄h ⁄ L) )0Æ49 0Æ02 )0Æ28 0Æ22
Spearman rank correlation was used to test the strength of the association between VEGF and the other variables. Significant results are highlighted in bold.
Figure 1 Acute response of vascular endothelial growth factor
(VEGF) to controlled hyperglycaemia in controls and obese
subjects with and without metabolic syndrome (MetS). Analy-
sis of covariance for repeated measures was used to assess
VEGF changes during acute hyperglycaemia after including age
in the model as covariate. Time (T) was the repeated measure
factor, and group (G) was entered as the between-subject
factor. The interaction term (T · G) was built to assess
between-group differences in VEGF responses during
hyperglycaemia. Error bars are SE.
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results warrant further investigation in larger clinical studies,
in particular with regard to their relevance for an enhanced
atherosclerotic risk in obesity and in patients with diabetes with
poorly controlled glycaemia.
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Figure S1: Plasma glucose and insulin concentrations during a FSIVGTT in normal weight and obese subjects 
divided according to the diagnosis of MetSynSymbols are: control group (O); obese NO-MetSyn (); obese-
MetSyn (). 
 
  
Exclusion Criteria 
 
Participants were excluded if they had any of the following: history of substance abuse or 
alcoholism; allergy or intolerance to intervention foods; pregnancy or breastfeeding; 
professional athletes; weight change more than 3 kg in the last month; diagnosis of 
malignancy; chronic and acute metabolic and inflammatory conditions likely to interfere with 
the study outcome; severe anemia (Hb < 10 mg/dL); type 1 diabetes and subjects with T2D if 
treated with insulin and/or oral hypoglycaemic agents; weight loss medications; drugs having 
an effect on either NO production or on insulin sensitivity (corticosteroids, phenytoin, 
erythromycin, sildenafil, diuretics,  laxatives, anticoagulants, antacids, nitrate derived agents, 
steroids, statins and any other anti-dyslipidaemic agent, including fibrates and nicotinic acid); 
Subjects taking antihypertensive agents, hormonal replacement therapies (estrogens, 
thyroxine, progesteron) and psychiatric drugs (antidepressants, sedatives, antipsychotics) 
were excluded if the dose had been started/changed in the previous six months. 
  
Dietary Plan 
Low Nitrate Diet (ONT method) 
It was essential to modify the diet to restrict NO3- intake for of both methods. Since NO3- 
occurs in both plants and water it is a natural component of human diet. Nitrate is used as a 
preservative in cured meat but fresh meat contains little NO3-. Fruit and grains have a small 
impact on dietary intake of NO3-. The diet and the meals used in this study were prepared on 
the basis of a recent report on NO3- content in food products1. Subjects were advised to avoid 
all vegetables, cooked and raw, and all tomato based products (spaghetti, pizza sauces, 
ketchup, tomato juice), potatoes, cured meat, seafood and fish, cheese, wines, beer, alcohol 
and tap water. Nitrate free water was provided during the study. On this protocol NO3- intake 
was expected to be <30 mg/day2.  
 
Very low nitrate meals (ONT method) 
The meals were served to each participant before the start of their 18-hr fasting period. The 
meals were formulated to have an energy content of ~1400 kcal and provide a NO3- intake <5 
mg/meal. The NO3- content of food was derived from a published report on NO3- content in 
food products1.Ingredients with very low NO3- content (<5mg/100g) were chosen (pasta, 
eggs, rice, cereals, oil and spreads, fruit, milk). Low NO3- bottled mineral water (0.1mg/l) was 
used for cooking the meals. Three meals were developed, and the subjects were allowed to 
choose the one the preferred as this was felt would improve compliance. The McCance-
Widdowson food composition tables were used to calculate the energy content of the meals3. 
The nutritional composition of the three meals is described in Table S1a, S1b and S1c.  
 
Table S1a: Meal 1 = Chicken Fried Rice 
Food Grams Nitrate (mg) /100g Total Nitrate (mg) Kcal/100g Total Kcal 
Chicken Breasts 100 1 1 155 155 
Egg 80 0.49 0.392 151 120.8 
Rice 90 2.5 2.25 383 344.7 
Vegetable oil 20 0 0 900 180 
Parmesan cheese 10 1.61 0.161 400 40 
Yoghurt 150 0.05 0.075 82 123 
Chocolate Mousse 120 0 0 300 360 
Chocolate 40 0 0 520 208 
Sliced Brown Bread 40 2.5 1 227 90.8 
Cream Cheese 35 0 0 162 56.7 
Butter 10 0 0 737 73.7 
Water Ad Lib 0 0   
Coffee/Tea Ad Lib 0 0   
Salt A bit 0 0   
Pepper A bit 0 0   
Total 695 8.15 4.878 4017 1752 
 
Table S1b: Meal 2 = Chicken Sandwich 
Food Grams Nitrate (mg) /100g Total Nitrate (mg) Kcal/100g Total Kcal 
Chicken Breasts 100 1 1 155 155 
Sliced Brown Bread 80 2.5 2 207 165.6 
Mayo 15 0 0 700 105 
Yoghurt 150 0.05 0.075 82 123 
Chocolate Mousse 120 0 0 300 360 
Chocolate 40 0 0 520 208 
Sliced Brown Bread 80 2.5 2 227 181.6 
Cream Cheese 35 0 0 162 56.7 
Butter 20 0 0 737 147.4 
Water Ad Lib 0 0   
Coffee/Tea Ad Lib 0 0   
Salt A bit 0 0   
Pepper A bit 0 0   
Total 640 6.05 5.075 3090 1502.3 
 
Table S1c: Meal 3 = Egg-Mayo Sandwich 
Food Grams Nitrate (mg) /100g Total Nitrate (mg) Kcal/100g Total Kcal 
Egg 160 0.49 0.784 151 241.6 
Sliced Brown Bread 80 2.5 2 207 165.6 
Mayo 15 0 0 700 105 
Yoghurt 150 0.05 0.075 82 123 
Chocolate Mousse 120 0 0 300 360 
Chocolate 40 0 0 520 208 
Sliced Brown Bread 80 2.5 2 227 181.6 
Cream Cheese 35 0 0 162 56.7 
Butter 20 0 0 737 147.4 
Water Ad Lib 0 0   
Coffee/Tea Ad Lib 0 0   
Salt A bit 0 0   
Pepper A bit 0 0   
Total 700 5.54 4.859 3086 1589 
Participants were invited to eat as much as they could. Food was weighted before and after 
consumption for the calculation of energy and nitrate intake. On average, volunteers ingested 
1406±322 kcal and 4.39±0.56mg of energy and nitrate, respectively. 
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